Glycosylphosphatidylinositol-modified murine B7-1 and B7-2 retain costimulator function.
Publication/Presentation Date
12-15-1995
Abstract
Glycosylphosphatidylinositol (GPI)-modified variants of murine B7-1 and B7-2 cell surface costimulators were produced via chimerization with alternative GPI-modification signal sequences from decay-accelerating factor (DAF). GPI anchorage was verified by demonstrating phosphatidylinositol-specific phospholipase C (PI-PLC) sensitivity of the chimeric polypeptides in both immunofluorescence/flow-cytometric and immunoprecipitation analyses. The various GPI-modified chimeric B7-1:DAF and B7-2:DAF polypeptides were shown to retain costimulator function, in both an in vitro proliferation assay and an in vivo triggering of cytotoxicity assay. The findings indicate that costimulator function for both B7-1 and B7-2 is not dependent upon native hydrophobic transmembrane anchorage. Moreover, the functionality of the GPI-modified variants in enhancing the immunogenicity of the murine T lymphoma line EL-4 suggests a novel route for generating APC-centered immunotherapeutics, including cellular cancer vaccines, that is based upon protein transfer of GPI-modified costimulators.
Volume
155
Issue
12
First Page
5498
Last Page
5505
ISSN
0022-1767
Published In/Presented At
Brunschwig, E. B., Levine, E., Trefzer, U., & Tykocinski, M. L. (1995). Glycosylphosphatidylinositol-modified murine B7-1 and B7-2 retain costimulator function. Journal of immunology (Baltimore, Md. : 1950), 155(12), 5498–5505.
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
7499830
Department(s)
Administration and Leadership
Document Type
Article